Compare SSR Mining Inc. Common Stock (SSRM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SSR Mining Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? SSR Mining Inc. Common Stock trades at $31 (market cap $6.72B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: SSR Mining Inc. Common Stock is the larger of the two by market cap, and SSR Mining Inc. Common Stock pays a 0.09% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold SSR Mining Inc. Common Stock for 1 Days and Tango Therapeutics Inc. for 0 Days on average.
| SSRM | TNGX | |
|---|---|---|
Market Cap | $6.72B | $3.75B |
Volume | 3,758,896 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $39.21 | $32.90 |
52-Week Low | $19.48 | $7.50 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $4.89B | $2.77B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SSR Mining (SSRM) trades at $33.09, down 6.63% amid recent volatility, yet maintains strong fundamentals with a P/E of 12.44 and net income margin of 12.3%. The company recently announced the $464 million acquisition of Roxmore Resources, which could add 170,000 ounces of annual gold production. Technical indicators show a bullish trend with support at $34-$35, while earnings have beaten expectations in two of the last three quarters.
The outlook remains positive with a consensus price target of $42.67 (29% upside), driven by strategic acquisitions and Americas-focused growth. Risks include execution of the Roxmore integration and gold price sensitivity. Analysts are bullish (73% buy ratings), citing the company's debt-free balance sheet and $1.8 billion cash position.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SSR Mining Inc. Common Stock
SSR Mining operates precious-metals mines in the United States, Canada, and Argentina. It produces gold doré and concentrates containing copper, silver, lead, and zinc.
Read more on SSRM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
